104 related articles for article (PubMed ID: 18398158)
1. No evidence for taxane/platinum pharmacogenetic markers: just lack of power?
Vach W; Bergmann TK; Brøsen K
J Clin Oncol; 2008 Apr; 26(11):1903-4; author reply 1904-5. PubMed ID: 18398158
[No Abstract] [Full Text] [Related]
2. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer.
Marsh S; Paul J; King CR; Gifford G; McLeod HL; Brown R
J Clin Oncol; 2007 Oct; 25(29):4528-35. PubMed ID: 17925548
[TBL] [Abstract][Full Text] [Related]
3. Current status of taxane and platinum-based chemotherapy in ovarian cancer.
McGuire WP
J Clin Oncol; 2003 May; 21(10 Suppl):133s-135s. PubMed ID: 12743128
[TBL] [Abstract][Full Text] [Related]
4. Ovarian-cancer results cause a stir at cancer conference.
McNamee D
Lancet; 2000 May; 355(9218):1890. PubMed ID: 10866453
[No Abstract] [Full Text] [Related]
5. Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers.
Markman M; Webster K; Zanotti K; Kulp B; Peterson G; Belinson J
Gynecol Oncol; 2004 Oct; 95(1):109-13. PubMed ID: 15385118
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemotherapy with carboplatin and taxane compared with single drug carboplatin in early stage epithelial ovarian carcinoma.
Skírnisdóttir I; Lindborg K; Sorbe B
Oncol Rep; 2007 Nov; 18(5):1249-56. PubMed ID: 17914581
[TBL] [Abstract][Full Text] [Related]
7. ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit.
Newman G
Lancet; 2003 Oct; 362(9392):1333; author reply 1334. PubMed ID: 14575996
[No Abstract] [Full Text] [Related]
8. Discordance of clinical symptoms and electrophysiologic findings in taxane plus platinum-induced neuropathy.
Pan Y; Kao MS
Int J Gynecol Cancer; 2007; 17(2):394-7. PubMed ID: 17362318
[TBL] [Abstract][Full Text] [Related]
9. [Combination chemotherapy with docetaxel and carboplatin for epithelial ovarian cancer].
Misawa H; Ochiai K; Yasuda M; Tanaka T
Nihon Rinsho; 2004 Oct; 62 Suppl 10():546-9. PubMed ID: 15535305
[No Abstract] [Full Text] [Related]
10. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study.
Kim HS; Kim MK; Chung HH; Kim JW; Park NH; Song YS; Kang SB
Gynecol Oncol; 2009 May; 113(2):264-9. PubMed ID: 19203783
[TBL] [Abstract][Full Text] [Related]
11. ABCB1 2677G>T/A genotype and paclitaxel pharmacogenetics in ovarian cancer.
Marsh S; King CR; McLeod HL; Paul J; Gifford G; Brown R
Clin Cancer Res; 2006 Jul; 12(13):4127; author reply 4127-9. PubMed ID: 16818714
[No Abstract] [Full Text] [Related]
12. Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials.
Regan MM; O'Donnell EK; Kelly WK; Halabi S; Berry W; Urakami S; Kikuno N; Oh WK
Ann Oncol; 2010 Feb; 21(2):312-318. PubMed ID: 19633053
[TBL] [Abstract][Full Text] [Related]
13. Taxane-based chemotherapy for patients with carcinoma of unknown primary site.
Greco FA; Gray J; Burris HA; Erland JB; Morrissey LH; Hainsworth JD
Cancer J; 2001; 7(3):203-12. PubMed ID: 11419028
[TBL] [Abstract][Full Text] [Related]
14. An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines.
Smith JA; Ngo H; Martin MC; Wolf JK
Gynecol Oncol; 2005 Jul; 98(1):141-5. PubMed ID: 15963813
[TBL] [Abstract][Full Text] [Related]
15. Mandating prospectively defined endpoints for ovarian cancer phase 2 trials: a strategy to improve the quality of gynecologic cancer clinical research.
Markman M
Gynecol Oncol; 2008 Sep; 110(3):275-7. PubMed ID: 18586312
[No Abstract] [Full Text] [Related]
16. Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer.
Vasey PA
J Clin Oncol; 2003 May; 21(10 Suppl):136s-144s. PubMed ID: 12743129
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas.
Matsuo K; Eno ML; Im DD; Rosenshein NB
Arch Gynecol Obstet; 2010 Feb; 281(2):325-8. PubMed ID: 19455347
[TBL] [Abstract][Full Text] [Related]
18. Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane. Results from a multicenter phase I/II study.
Gronlund B; Engelholm SA; Horvath G; Mäenpää J; Ridderheim M
Cancer; 2005 Apr; 103(7):1388-96. PubMed ID: 15719439
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy of advanced ovarian cancer.
Martoni A; Cacciari N; Angelelli B; Zamagni C; Pannuti F
Front Biosci; 1997 Mar; 2():g20-6. PubMed ID: 9159262
[TBL] [Abstract][Full Text] [Related]
20. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.
Sessa C; De Braud F; Perotti A; Bauer J; Curigliano G; Noberasco C; Zanaboni F; Gianni L; Marsoni S; Jimeno J; D'Incalci M; Dall'ó E; Colombo N
J Clin Oncol; 2005 Mar; 23(9):1867-74. PubMed ID: 15774779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]